Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Aravive flunks Phase 3 in platinum-resistant ovarian cancer

Aravive’s (NASDAQ:ARAV) Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre...

August 3, 2023

Developments

Oramed, Hefei Tianhui in JV to advance oral drug delivery technology

Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) signed a non-binding term sheet with Hefei Tianhui Biotech to establish a joint venture based on Oramed’s oral drug delivery technology. The proposed JV would focus on...

August 2, 2023

Developments

NeuroBo in out-licensing with MThera Pharma

NeuroBo Pharmaceuticals (NASDAQ:NRBO) entered into a term sheet with MThera Pharma detailing terms that NeuroBo will out-license the worldwide rights, outside of Korea, for NB-01 for the treatment of painful diabetic...

August 2, 2023

Developments

Avenue Therapeutics achieves high potency and full efficacy in a model of generalized seizures

Avenue Therapeutics’ (NASDAQ:ATXI) BAER-101, its potentially best-in-class selective GABA-A alpha2,3 positive allosteric modulator significantly suppressed seizures in a translational animal model of absence epilepsy...

August 1, 2023

Markets

Cantor starts Health Catalyst at OW; PT $16

Cantor Fitzgerald launched coverage of Health Catalyst (NASDAQ:HCAT) with an “overweight” rating and price target of $16, representing a 2024 enterprise value/revenue multiple of 2.3 times. The stock closed at $14.03 on...

August 1, 2023

Developments

IntelGenx completes enrollment in Montelukast VersaFilm Phase 2a trial in AD

IntelGenx (TSX:IGX; OTCQB:IGXT) completed patient enrollment in the ongoing Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD). The company successfully...

August 1, 2023

Markets

Cantor starts Belite Bio at OW; PT $43

Cantor Fitzgerald launched coverage of Belite Bio (NASDAQ:BITR) with an “overweight” rating and a 12-month price target of $43. Belite listed its ADSs on NASDAQ in April 2022; they closed at $20.55 on July 27. Belite...

July 28, 2023

Markets

Leerink slashes Mersana PT to $4 after UPLIFT trial fails

Leerink slashed its price target for Mersana Therapeutics (NASDAQ:MRSN) to $4 from $15, but maintained its “outperform” rating after the UPLIFT clinical trial of upifitamab rilsodotin (UpRi) did not meet its primary...

July 27, 2023

Developments

Anixa Biosciences receives U.S. notice of additional ovarian cancer vaccine patent

The U.S. Patent and Trademark Office (USPTO) issued a notice of allowance broadening protection of Anixa Biosciences’ (NASDAQ:ANIX) novel ovarian cancer vaccine technology, which has been exclusively licensed from, and...

July 27, 2023

Developments

Titan Pharma to sell certain ProNeura assets

Titan Pharmaceuticals (NASDAQ:TTNP) entered into an asset purchase agreement with Fedson for the sale of certain ProNeura assets, including Titan’s portfolio of drug addiction products, in addition to other early...

July 27, 2023

Developments

Carmell to merge with Axoloti Biologix

Carmell Therapeutics (NASDAQ:CTCX) signed a definitive agreement and plan of merger with Axoloti Biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and...

July 27, 2023

Developments

Humacyte completes Phase 2/3 enrollment in vascular trauma repair

Humacyte (NASDAQ:HUMA) completed enrollment of its Phase 2/3 vascular trauma trial that is expected to support a BLA filing for Humacyte’s human acellular vessel (HAV) in vascular trauma repair planned for the fourth...

July 26, 2023

Aravive flunks Phase 3 in platinum-resistant ovarian cancer

Oramed, Hefei Tianhui in JV to advance oral drug delivery technology

NeuroBo in out-licensing with MThera Pharma

Avenue Therapeutics achieves high potency and full efficacy in a model of generalized seizures

Cantor starts Health Catalyst at OW; PT $16

IntelGenx completes enrollment in Montelukast VersaFilm Phase 2a trial in AD

Cantor starts Belite Bio at OW; PT $43

Leerink slashes Mersana PT to $4 after UPLIFT trial fails

Anixa Biosciences receives U.S. notice of additional ovarian cancer vaccine patent

Titan Pharma to sell certain ProNeura assets

Carmell to merge with Axoloti Biologix

Humacyte completes Phase 2/3 enrollment in vascular trauma repair

General

More